Testosterone Enanthate Travel & Timezone-Shift Protocols

What the label specifies for timing

The intramuscular testosterone enanthate label (Hikma's generic) gives 50 to 400 mg every 2 to 4 weeks for male hypogonadism. It notes that, in general, total doses above 400 mg per month are not required because of the prolonged action of the preparation [1]. Before treatment it requires a confirmed diagnosis: morning serum testosterone measured on at least two separate days, both values below the normal range [1]. Enanthate is an oil-soluble testosterone ester, absorbed slowly from the injected oil depot and split into free testosterone.

Because the label writes the interval in weeks and says nothing about time zones, it gives no basis for a clock-hour adjustment when crossing time zones [1].

Giving the injection away from home

The label directs a slow, deep injection into the gluteal muscle with the usual precautions for intramuscular administration, including avoiding intravascular injection [1]. Xyosted, a subcutaneous enanthate autoinjector, is a different product with its own route and its own label.

The label also says parenteral products should be inspected visually for particulate matter and discoloration, and that enanthate is a clear, colorless to pale yellow solution [1]. A wet needle or wet syringe may make the solution cloudy, which the label says does not affect potency [1].

What the label says to watch for

• Venous thromboembolism. Deep vein thrombosis and pulmonary embolism have been reported with testosterone products such as enanthate. The label says to evaluate lower-extremity pain, edema, warmth or erythema for DVT, and acute shortness of breath for PE. If a venous thromboembolic event is suspected, the label says to discontinue testosterone enanthate and start appropriate workup and management [1].
• Blood pressure. Testosterone can raise blood pressure, which can raise cardiovascular risk over time; the label says to monitor blood pressure periodically, especially in men with hypertension, and that testosterone products are not recommended in uncontrolled hypertension [1].
• Fluid retention. Edema with or without congestive heart failure can be a serious complication in men with preexisting cardiac, renal or hepatic disease [1].
• Red cell mass. Polycythemia is in the enanthate label's adverse reaction list [1]. In a network meta-analysis of 29 placebo-controlled trials in 3,393 men, intramuscular enanthate or cypionate raised mean hematocrit by 4.0 percent (95% CI 2.9 to 5.1) versus placebo [3]. The Endocrine Society's 2018 guideline recommends monitoring symptoms, serum testosterone, hematocrit and prostate cancer risk during the first year of therapy [4].

US legal status

Testosterone is a Schedule III controlled substance under US federal law [2], and the enanthate label states Schedule III [1].